Results 41 to 50 of about 6,038 (211)

Urologic Bacteriome: The Hero or the Villain in Prostate Cancer Onset, Progression, and Treatment?

Medicinal Research Reviews, Volume 46, Issue 4, Page 1111-1151, July 2026.
ABSTRACT Prostate cancer (PCa) is the second most frequently diagnosed cancer in men worldwide and the fifth leading cause of cancer‐related mortality, presenting urgent unmet clinical needs in diagnosis and treatment. The recognition of the microbiome as a key factor in human health has prompted numerous studies, revealing an exciting new approach to ...
Lara R. S. Fonseca, Mariana Feijó, Cátia V. Vaz, Bruno J. Pereira, Sandra Laurentino, Ana Palmeira‐de‐Oliveira, Sílvia Socorro   +6 more
wiley   +1 more source

Different sensitivity of CD30+ cell lines to Ber-H2/saporin-S6 immunotoxin

, 1998
The in vitro sensitivity of cells to a Ber-H2(anti-CD30)/saporin-S6 immunotoxin has been investigated. The CD30+ cell lines, K562, L428 and L540, were used to study cell binding, uptake and degradation of the immunotoxin.
Olivieri F., Polito L., Bolognesi A., Stirpe F., Battelli M. G.   +4 more
core   +1 more source

Anti-Human Endoglin (hCD105) Immunotoxin—Containing Recombinant Single Chain Ribosome-Inactivating Protein Musarmin 1

Toxins, 2016
Endoglin (CD105) is an accessory component of the TGF-β receptor complex, which is expressed in a number of tissues and over-expressed in the endothelial cells of tumor neovasculature.
Begoña Barriuso, Pilar Antolín, F. Javier Arias, Alessandra Girotti, Pilar Jiménez, Manuel Cordoba-Diaz, Damián Cordoba-Diaz, Tomás Girbés   +7 more
doaj   +1 more source

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

Advanced Science, Volume 13, Issue 35, 24 June 2026.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun, Haochen Yang, Qing Xu, Xingya Li, Jinxing Lou, Jianchun Duan, Jiachen Xu, Zhuqing Liu, Yong Xia, Zhicai Lin, Linlin Li, Dan Sun, Jiaguo Li, Tao Liu, Jun Guo, Wenfeng Xu, Weimin Zhu, Yi Liu, Boyang Sun, Jia Zhong, Lijie Rong, Qijun Qian, Chenqi Xu, Jie Wang   +23 more
wiley   +1 more source

Development of a new minimally invasive phototherapy for lung cancer using antibody–toxin conjugate

Thoracic Cancer, 2023
Background Photodynamic therapy (PDT) is a cancer‐targeted treatment that uses a photosensitizer (PS) and laser irradiation. The effectiveness of current PDT using red light for advanced cancers is limited, because red light can only reach depths within ...
Takumi Sonokawa, Naoko Obi, Jitsuo Usuda, Yukio Sudo, Takao Hamakubo   +4 more
doaj   +1 more source

Development of Novel CD47-Specific ADCs Possessing High Potency Against Non-Small Cell Lung Cancer in vitro and in vivo

Frontiers in Oncology, 2022
Targeted therapies hold promise for efficiently and accurately delivering cytotoxic drugs directly to tumor tissue to exert anticancer effects. CD47 is a membrane protein expressed in a variety of malignant tumors and hematopoietic cells, which plays a ...
Zu-Chian Chiang, Zu-Chian Chiang, Zu-Chian Chiang, Shubin Fang, Yang-kun Shen, Dongya Cui, Huanjiao Weng, Dawei Wang, Yuxiang Zhao, Jizhen Lin, Jizhen Lin, Qi Chen   +11 more
doaj   +1 more source

Delivering Proteins and Enzymes to Solid Tumors Through the Development of Stimuli‐Responsive Nanocarriers

ChemNanoMat, Volume 12, Issue 6, June 2026.
Stimuli‐responsive strategies to achieve controlled release of protein‐based therapeutic agents into solid tumors. Proteins, enzymes, and peptides have long been recognized as valuable therapeutic agents, particularly in oncology. However, their complex chemical structures render them more sensitive than smaller chemotherapeutic drugs.
Guillermo Plaza‐Palomo, Diana Benita‐Donadios, Sandra Jiménez‐Falcao, Alejandro Baeza   +3 more
wiley   +1 more source

Immunotoxin: A new tool for cancer therapy

, 2017
Cancer is one of the main reasons of death in the most countries and in Iran. Immunotherapy quickly became one of the best methods of cancer treatment, along with chemotherapy and radiation.
Mehdi Ghamgosha, Parvaneh Saffarian, Hossein Allahyari, Sahar Heidari, Jafar Amani   +4 more
core   +1 more source

Edulitin 2, a Ribotoxin‐Like Protein From Boletus edulis That Triggers Apoptosis in Colon Cancer Cells While Preserving the Integrity of the Intestinal Microbiota

eFood, Volume 7, Issue 3, June 2026.
Edulitin 2 is a ribotoxin‐like protein exhibiting a potent antiproliferative activity towards Caco‐2 and HT29 cells by programmed cell death. However, edulitin 2 does not affect gut microbiota growth, despite damaging fungal ribosomes. ABSTRACT Porcini (Boletus edulis Bull.) are a reservoir of pharmacological biomolecules with health‐promoting ...
Massimo Bortolotti, Sara Ragucci, Federica Falà, Anella Saggese, Francesco Biscotti, Ylenia De Luca, Nicola Landi, Paolo V. Pedone, Andrea Bolognesi, Ezio Ricca, Letizia Polito, Antimo Di Maro   +11 more
wiley   +1 more source

Construction of a recombinant immunotoxin [PDF]

, 1995
University of Technology, Sydney. Faculty of Science.In recent years a number of therapeutically useful immunotoxins have been produced using recombinant gene technology.

core